GlassScriptPhysician profile
Adam Nikolas Davis
NPI 1467015628
$894.89
in general payments reported to CMS, 2019-2025
15 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $77.73 · 2023: $307 · 2024: $247 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $817.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $251.40 | 2023 | Minimed 780g |
| Kerecis Limited | $157.86 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Inspire Medical Systems, INC. | $137.64 | 2025 | Inspire |
| Corcept Therapeutics | $52.57 | 2025 | Korlym |
| Kyowa Kirin, INC. | $46.58 | 2024 | Crysvita |
| Sequel Med Tech, LLC | $39.27 | 2025 | Twiist |
| Dexcom, INC. | $36.34 | 2023 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $34.04 | 2025 | Isturisa |
| Fresenius USA Marketing, INC. | $23.08 | 2022 | |
| Pfizer INC. | $22.99 | 2024 | |
| Amgen INC. | $22.86 | 2022 | |
| Abbvie INC. | $19.48 | 2024 | |
| Insulet Corporation | $18.99 | 2023 | Omnipod |
| Lilly USA, LLC | $16.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.